As the VMware vSphere 7 Support Deadline Nears, Spinnaker Announces Alternative Option to Keep VMware Customers Supported Indefinitely
22.9.2025 14:00:00 CEST | Business Wire | Press Release
Spinnaker Support (Spinnaker), the Oracle, SAP and VMware software support specialist trusted by over 1,000 global clients, including many of the world’s leading banks, telcos and utility companies, announces today that it will provide support for organizations running vSphere 7 indefinitely - meaning organizations running vSphere 7 for as long as they want past Broadcom’s End of General Support Deadline (EoGS) of October 2, 2025.
From October 2, 2025, Broadcom will no longer provide technical support, security patches, or updates for vSphere 7.x, and customers will need to upgrade to a newer version if they want to remain supported. If customers decide not to upgrade or simply don’t have the budget to do so, systems will become vulnerable.
“Broadcom is essentially telling customers “Upgrade now or you’ll be left behind”, and we believe that is wrong,” said Shane O'Rourke, Senior Director of VMware Global Support Services, Spinnaker Support. “This is why today we are announcing that VMware customers running vSphere 7 can continue to do so as long as they want and remain supported by our team of VMware experts. This once again demonstrates Broadcom’s attitude towards customers and ultimately forcing them to upgrade when they are happy with their current version.”
“Many of the customers I talk to are still running on version 7, often because it’s “just working” and nobody wants to fix what isn’t broken. But as support winds down, the risks for these customers only compound: no more CVEs, no more zero-day patches, and no guarantees if something fundamental fails. From my perspective, now is the time to step back and look at what’s actually right for your business, your use cases, and your environment, not just what the vendor lifecycle dictates,” added O’Rourke.
David McDougall, CRO, Spinnaker Support commented: “Since the Broadcom acquisition, ambiguity is the only thing we’ve been able to count on. Customers distrust the licensing changes, many outright reject the move to a subscription model, and most simply want to avoid getting caught in another round of sudden price hikes, changing terms, or forced upgrades driven by the vendor. VMware has unwittingly pushed many customers into running their environments unsupported. The decision to shed your support contract isn’t something anyone is doing without serious consideration, and many customers feel like they have no alternative in the face of the VMware changes. It’s critical that organizations know that there is an alternative support option available to them.”
For more information about Spinnaker Support’s VMware support offering, visit https://www.spinnakersupport.com/vmware/.
About Spinnaker Support
Spinnaker Support is entrusted by over 1,000 companies worldwide to solve their most pressing and essential enterprise software needs.
Spinnaker Support experts provide an extensive services portfolio of third-party support, managed services, consulting, and state-of-the-art security to optimize clients’ software ecosystems. They support Oracle, SAP, and VMware – freeing up valuable capital and resources so customers can maximize the security and performance of their enterprise software ecosystem with certainty. With Spinnaker, enterprises are empowered to make software decisions based on their business initiatives rather than their enterprise software provider’s roadmap.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922678118/en/
Contacts
Media contact
Dan Walsh
dan@mustardpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom